Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Frezza, AM; Cesari, M; Baumhoer, D; Biau, D; Bielack, S; Campanacci, DA; Casanova, J; Esler, C; Ferrari, S; Funovics, PT; Gerrand, C; Grimer, R; Gronchi, A; Haffner, N; Hecker-Nolting, S; Höller, S; Jeys, L; Jutte, P; Leithner, A; San-Julian, M; Thorkildsen, J; Vincenzi, B; Windhager, R; Whelan, J.
Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study.
Eur J Cancer. 2015; 51(3):374-381 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Leithner Andreas
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Mesenchymal chondrosarcoma (MCS) is a distinct, very rare sarcoma with little evidence supporting treatment recommendations. Specialist centres collaborated to report prognostic factors and outcome for 113 patients. Median age was 30 years (range: 11-80), male/female ratio 1.1. Primary sites were extremities (40%), trunk (47%) and head and neck (13%), 41 arising primarily in soft tissue. Seventeen patients had metastases at diagnosis. Mean follow-up was 14.9 years (range: 1-34), median overall survival (OS) 17 years (95% confidence interval (CI): 10.3-28.6). Ninety-five of 96 patients with localised disease underwent surgery, 54 additionally received combination chemotherapy. Sixty-five of 95 patients are alive and 45 progression-free (5 local recurrence, 34 distant metastases, 11 combined). Median progression-free survival (PFS) and OS were 7 (95% CI: 3.03-10.96) and 20 (95% CI: 12.63-27.36) years respectively. Chemotherapy administration in patients with localised disease was associated with reduced risk of recurrence (P=0.046; hazard ratio (HR)=0.482 95% CI: 0.213-0.996) and death (P=0.004; HR=0.445 95% CI: 0.256-0.774). Clear resection margins predicted less frequent local recurrence (2% versus 27%; P=0.002). Primary site and origin did not influence survival. The absence of metastases at diagnosis was associated with a significantly better outcome (P<0.0001). Data on radiotherapy indications, dose and fractionation were insufficiently complete, to allow comment of its impact on outcomes. Median OS for patients with metastases at presentation was 3 years (95% CI: 0-4.25). Prognosis in MCS varies considerably. Metastatic disease at diagnosis has the strongest impact on survival. Complete resection and adjuvant chemotherapy should be considered as standard of care for localised disease. Copyright © 2014 Elsevier Ltd. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Adolescent -
Adult -
Aged -
Aged, 80 and over -
Bone Neoplasms - diagnosis
Bone Neoplasms - epidemiology
Bone Neoplasms - therapy
Child -
Chondrosarcoma, Mesenchymal - diagnosis
Chondrosarcoma, Mesenchymal - epidemiology
Chondrosarcoma, Mesenchymal - therapy
Chondrosarcoma, Mesenchymal - epidemiology
Female -
Humans -
Male -
Middle Aged -
Prognosis -
Societies, Medical -
Young Adult -

Find related publications in this database (Keywords)
Mesenchymal chondrosarcoma
Chemotherapy
Outcome
© Meduni Graz Impressum